NASDAQ:PRPH - ProPhase Labs Stock Price, Forecast & News

ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."

ProPhase Labs announced a dividend on Wednesday, November 20th. Stockholders of record on Tuesday, December 3rd will be paid a dividend of $0.25 per share on Thursday, December 12th. The ex-dividend date of this dividend is Monday, December 2nd. View ProPhase Labs' Dividend History.

ProPhase Labs Inc (NASDAQ:PRPH) posted its quarterly earnings data on Monday, August, 12th. The company reported ($0.11) EPS for the quarter. The firm had revenue of $1.65 million for the quarter. ProPhase Labs had a negative net margin of 29.05% and a negative return on equity of 20.48%. View ProPhase Labs' Earnings History.

ProPhase Labs is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for ProPhase Labs.

Media stories about PRPH stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ProPhase Labs earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for ProPhase Labs.

ProPhase Labs saw a drop in short interest during the month of January. As of January 15th, there was short interest totalling 7,800 shares, a drop of 29.1% from the December 31st total of 11,000 shares. Based on an average daily volume of 3,000 shares, the short-interest ratio is presently 2.6 days. Currently, 0.1% of the company's stock are short sold. View ProPhase Labs' Current Options Chain.

Some companies that are related to ProPhase Labs include Oncolytics Biotech (ONCY), Catalyst Biosciences (CBIO), Stealth BioTherapeutics (MITO), Infinity Pharmaceuticals (INFI), Synlogic (SYBX), CTI BioPharma (CTIC), Elite Pharmaceuticals (ELTP), Onconova Therapeutics (ONTX), Entasis Therapeutics (ETTX), Eyenovia (EYEN), Chembio Diagnostics (CEMI), Trevena (TRVN), Catabasis Pharmaceuticals (CATB), ASLAN PHARMACEU/ADR (ASLN) and Cumberland Pharmaceuticals (CPIX).

Based on aggregate information from My MarketBeat watchlists, some companies that other ProPhase Labs investors own include NovaBay Pharmaceuticals (NBY), Rigel Pharmaceuticals (RIGL), Bausch Health Companies (BHC), Protalix Biotherapeutics (PLX), Akari Therapeutics (AKTX), Biocept (BIOC), CymaBay Therapeutics (CBAY), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

Shares of PRPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRPH stock can currently be purchased for approximately $1.78.

ProPhase Labs has a market capitalization of $20.62 million and generates $13.13 million in revenue each year. ProPhase Labs employs 47 workers across the globe.View Additional Information About ProPhase Labs.

The official website for ProPhase Labs is http://www.prophaselabs.com/.

ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The company can be reached via phone at 215-345-0919 or via email at [email protected]